CAR-T boxed warnings: What comes next?

The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This decision follows an investigation into the new safety signal from postmarketing adverse event reports and clinical trials. 

In today’s episode, Fierce Pharma’s Angus Liu talks with regulatory experts Mwango Kashoki, M.D., and Steve Winitsky, M.D., to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line.

Return to Insights Center

Related Insights

Article

Three ways to improve your chances that insurers will pay for a new CGT

Feb 18, 2021

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Blog

CAR-T boxed warnings: regulatory precedents and opportunities

Feb 9, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Blog

CAR-T product development: an assessment of FDA’s final guidance for industry

Feb 27, 2024

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Podcast

Rare endpoints: Delivering on unmet patient needs

May 7, 2024

Video

Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022

Blog

Key implications for nonclinical development: FDA guidance on human gene therapy products incorporating human genome editing

Jul 1, 2024

Blog

U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022

Podcast

RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022